ASX Capital Raise Roundup: Plenty of activity to report but IPOs remain weak

Link copied to
clipboard

ASX Capital Raise Roundup is a fortnightly look at ASX capital raisings.

This was an extremely active week with capital raises and the big question is, “Why?”

We suspect it has something to do with companies issuing their respective quarterly activity reports.

These documents give investors insights into companies’ business dealings over the past 90 days and, importantly, their respective cash positions. With full disclosures now in the public domain, they are free to issue more shares.

An example is this week’s Sensera Ltd (ASX:SE1) capital raise at $0.03 per share.

Strong performer Alligator Energy Limited (ASX:AGE) issued $10m at $0.027 per share with the funds being applied to its flagship Samphire Uranium Project and other endeavours.

These companies have upcoming significant activities and are securing the necessary capital.

We are also noticing a firming trend in the medical sectors with the US biotechnology index hitting fresh highs and companies such as Anteris Technologies LTD (ASX:AVR) offering well-received capital raises.

On the Initial Public Offering side, market weakness continues and only companies with a clear path towards profitability and milestones such as Aquirian Limited (ASX:AQN) are trading at premiums. Of particular note, US darling Robinhood (NASDAQ:HOOD) is already trading at ~$32.00, down from its IPO price of $38.
 

Placements this week

Imugene Limited (ASX:IMU) has raised $90m to new and existing institutional and sophisticated investors at 30c per share. The placement received cornerstone interest from specialist biotech institutional investors.

The company is looking to raise a further $5m through a Share Purchase Plan at the same price as the placement.

Investors will receive one free attaching option for every two shares subscribed for in the offer with an exercisable price of 45c. The capital raised will be used to fund Imugene’s clinical trial pipeline through to the end of 2025.

Australian Mines Limited (ASX:AUZ) has raised $6.5m at 1.9c per share. Strong support for the placement was received from institutional investors both domestically and internationally.

Canaccord Genuity acted as lead manager and bookrunner to the placement.

Australian Mines managing director, Benjamin Bell, commented: “I am pleased with the strong support from both offshore and domestic investors for the Placement.

“This is an indication of the strengthening battery materials market and Australian Mines’ future role as a large-scale, long life battery materials producer.

“We will now be producing P-CAM samples in addition to continuing to produce nickel and cobalt sulphate samples, which will help secure offtake agreements with various international battery and motor vehicle manufacturers”.

JatCorp Limited (ASX:JAT) has raised $3m through a successful placement managed by Everblu Capital.

The placement was completed at 1.9c per share, with investors receiving a free 1-for-2 option with a strike price of 5c, and a two-year expiry date.

Funds will be used for machinery for its ANMA manufacturing facility, investments in production of goods for sale, and working capital.

JatCorp is a leading producer of supplementary food products and plant-based meat. JatCorp has a track record of successful product development and distinguished technology.

Melbana Energy Limited (ASX:MAY) has secured underwriting for a pro rate non-renounceable entitlement offer of two fully paid shares for every 13 shares held at the record date.

Investors will also receive a free 1-for-2 option, exercisable at 3.5c with a one-year expiry date. 180 Markets was pleased to assist Canaccord Genuity with the underwriting of this offer and received strong demand.

Shaun Factor, co-founder of 180 Markets said: “It is great to see companies like this offering their shareholders to fund the future prospects of the company.

“The sub-underwriting was a very popular method for new investors as they will receive 1 sub-underwriter commitment option for every 1 share sub-underwritten which are the same terms as the attaching options in the rights issue.”

The offer price of the raise was at discount of 16% to the previous trading price.

Alligator Energy (ASX:AGE) is currently in a trading halt for a $10m capital raise at 2.7c per share. The raise was done at a massive 25% discount to the last price of 3.6c per share.

180 Markets has huge interest for this deal which was done at almost 4X the price of the last raise for which 180 Markets was the lead manager.

AGE is a uranium-focused project development and exploration company, targeting multi-jurisdictional resource and exploration projects with clear pathways for approval and development. The funds for this raise will be used on its Samphire and ARUP Programs as well as general working capital.

Pointsbet Holdings Limited (ASX:PBH) is currently in a trading halt for a placement and a 1-for-9 entitlement offer to raise a total of $400m.

The placement will be priced at $10 per share while the entitlement offer will be at a lower price of $8 per share.

Funds raised under this offer will be used for North American marketing and client acquisition, technology and product development, US market access and government licensing fees, continued investment in talent and scale of operation as well as balance sheet flexibility.
 

Thinking about taking the IPO leap?

share

• 
• 
• 
• 

Link copied to
clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

Name*

Email*

This field is hidden when viewing the form

Email Lists

Morning Update

Lunch Update

Market Close Update

Weekend Update

Spotlight

Phone

This field is for validation purposes and should be left unchanged.

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.

You might be interested in

News

ASX Capital Raise Roundup: Arise, Sir Lithium

August 13, 2021 | 180 Markets

Health & Biotech

Biocurious: Painchek’s aged care and infant market expansion plans could be much-needed salve

December 18, 2024 | Tim Boreham

Health & Biotech

Health Check: Hearts are pumping as Anteris shares debut on the Nasdaq 

December 16, 2024 | Tim Boreham